Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2013)
17 slides from Idt Australia's shareholder meeting presentation, Nov 20, 2013
Slide 1: IDT Australia Limited AGM Presentation, November 2013
For personal use only IDT AUSTRALIA LIMITED (ASX: IDT) AGM PRESENTATION, NOVEMBER 2013
Slide 2: Our Goal Today
OUR GOAL TODAY For personal use only • EXPLAIN THE ACTIONS FOR THE GROWTH OF OUR EXISTING BUSINESSES • INTRODUCE THE ‘NEW IDT’ – NEW VISION, NEW BUSINESS, NEW PARTNERS • COMMUNICATE THE LONGER TERM DIRECTION AND INTENTIONS OF IDT • EXPLAIN PATH TO RETURN TO PROFITABILITY
Slide 3: Who is IDT?
WHO IS IDT? For personal use only • AUSTRALIA’S OLDEST AND MOST EXPERIENCED DEVELOPER OF PHARMACEUTICALS • UNSURPASSED MANUFACTURING ASSETS • KNOWLEDGE AND EXPERIENCE FOR SIGNIFICANT GROWTH THROUGH ORGANIC EXPANSION AND THE DEVELOPMENT OF IDT SPECIALTY GENERIC PORTFOLIO • CMAX CLINICAL ASSETS AND BO
Slide 4: Blueprint for Success
BLUEPRINT FOR SUCCESS For personal use only IDT’S BUSINESSES ARE INDEPENDENT BUT COMPLEMENTARY 30 YEARS DRUG DEVELOPMENT 20 YEARS CLINICAL AND MANUFACTURING DEVELOPMENT AND EXPERIENCE BIOEQUIVALENCE EXPERIENCE • METHOD DEVELOPMENT • CMAX PHASE I AND PK • ANALYTICAL DEVELOPMENT EXPERTISE • SCALE-UP A
Slide 5: FY2013 Results
FY2013 RESULTS For personal use only • REVENUE IMPROVEMENT OF 7% OVER FY12 TO $10.7M • DRIVING FOR FURTHER GROWTH THIS YEAR IDT Revenue Trend 14.000 12.000 10.000 8.000 Revenue (millions) 6.000 4.000 2.000 - 2011 2012 2013 • NEW MANAGEMENT TEAM 2013/14 WITH MORE URGENT COMMERCIAL FOCUS • DEDICATED B
Slide 6: Grow Existing Business
GROW EXISTING BUSINESS For personal use only • #1 PRIORITY TO RETURN EXISTING BUSINESS TO PROFITABILITY • INCREASED FOCUS ON SALES AND MARKETING • INCREASE CAPACITY UTILIZATION AND RETURNS • WORKING WITH I’ROM TO BUILD NEW ORGANIC BUSINESS IN JAPAN • DRIVE TO RECREATE THE DECADES OF SUCCESS
Slide 7: Growth Initiatives
GROWTH INITIATIVES For personal use only • ‘GET URGENT’ • LOOK TO A WIDER CUSTOMER GROUP INCLUDING GENERIC PHARMA AND BIOTECH IN ADDITION TO BIG PHARMA • RECIPROCAL AND CO-MARKETING PARTNERSHIPS • EXPANSION INTO JAPANESE MARKET VIA I’ROM, 2 VISITS TO DATE • ACTIVELY MARKETING A WIDER RANGE OF SERVIC
Slide 8: Abbreviated New Drug Application (ANDA)
ABBREVIATED NEW DRUG APPLICATION (ANDA) For personal use only • PROCESS FOR REGISTERING A GENERIC DRUG IN THE US • WE HAVE PARTICIPATED IN DRUG REGISTRATIONS MANY TIMES • IDT COSTS LOW DUE TO ABILITY DO ALL ACTIVITIES IN HOUSE 3 EXHIBITION BATCHES CMC PACKAGE (6 MONTHS STABILITY DATA + BIOEQUIVALENC
Slide 9: Generic Pharma Industry
GENERIC PHARMA INDUSTRY For personal use only • IDT PREFERRED MARKETING PARTNERS AMONG THOSE LISTED AT LEFT • THE GLOBAL GENERICS MARKET WAS $225 BILLION IN 2011 • EXPECTED TO RISE TO $358 BILLION BY 2016 US$10B 2012 • REPRESENTS MORE THAN 18% OF ALL PHARMACEUTICALS BY VALUE • PROJECTED COMPOUND ANN
Slide 10: Generic Oncology Opportunities
GENERIC ONCOLOGY OPPORTUNITIES • IDT FILED TEMOZOLOMIDE ANDA Nov2013 For personal use only • MANY MORE HIGH VALUE ONCOLOGY DRUGS COMING OFF PATENT IN THE COMING YEARS TEMOZOLOMIDE FACTS • $918M PRODUCT GLOBALLY 2012 (Temodar®, BioPharm Insight) • CAPSULES FOR THE TREATMENT OF MELANOMA AND BRAIN CANC
Slide 11: How Will We Access This?
HOW WILL WE ACCESS THIS? For personal use only • SEQUENTIALLY REGISTER OUR OWN GENERIC, MOSTLY ONCOLOGY DRUGS • IDT MANUFACTURING AND CLINICAL ASSETS SUPPORT THIS • MOVING FROM BEING SOLELY A SERVICE PROVIDER TO A REGISTRANT WILL INCREASE OUR SHARE OF THE WHOLESALE PRICE • IDT’S SHARE OF THE MARKETE
Slide 12: Moving Up the Value Chain
MOVING UP THE VALUE CHAIN • MARKET SHARE FOR GENERIC DRUGS DEPENDS UPON For personal use only CHANNEL AND UPON PARTNER SELECTION • REVENUE/PROFIT SPLIT OF THE WHOLSALE PRICE DEPENDS UPON TYPE OF DRUG (HIGHER FOR HARD TO MANUFACTURE OR SCARCE DRUGS) AND CHANNEL E.G. $300M DRUG $60M MARKET SHARE $20M
Slide 13: Real Example: Case Study, Drug X
REAL EXAMPLE For personal use only • CASE STUDY, DRUG X: 0.59% • IDT THE DOMINANT SUPPLIER OF API INTO A LARGE MARKET, YET CAPTURING LESS THAN 1% OF W/S PRICE 50.00% 49.41% • REGISTRATION AND SUPPLY OF FINISHED DOSE FORM COULD INCREASE IDT’S SHARE OF VALUE CHAIN TO API ($m) APPROXIMATELY 50% FDF ($m
Slide 14: 2013 Summary
2013 SUMMARY For personal use only • NEW MANAGEMENT TEAM • BOARD RENEWAL • IMPROVED BUSINESS DEVELOPMENT FUNCTION • EXPANSION STRATEGY TO LEVERAGE ASSETS • STRATEGY AND PLATFORM FOR FUTURE GROWTH
Slide 15: 2014 Outlook
2014 OUTLOOK For personal use only • FOCUS ON IMPROVEMENT OF ORGANIC BUSINESS RESULTS • JAPANESE BUSINESS ACTIVITY EXPANSION • IDT’S FIRST GENERIC FILING IN THE US FOR TEMOZOLOMIDE • ONE OR MORE ADDITIONAL HIGH VALUE DRUGS TO BE ACTIONED THIS YEAR • DISTRIBUTION DEALS TO FOLLOW
Slide 16: IDT Opportunity
IDT OPPORTUNITY For personal use only • EXISTING BUSINESS GROWTH PROVIDES REVENUES, CASH FLOWS AND DOWNSIDE PROTECTION • BROADENING OF IDT FROM SERVICE PROVIDER TO SPECIALTY PHARMA COMPANY • POSITIVE EFFECTS ON FUTURE BUSINESS IN THE SHORT TO MEDIUM TERM • CONTINUE TO BUILD AND SUPPORT BASE BUSINESS
Slide 17: IDT Australia Limited
For personal use only IDT AUSTRALIA LIMITED (ASX: IDT) AGM PRESENTATION, NOVEMBER 2013